UNLABELLED: One of the pathways leading to androgen independence in prostate cancer involves upregulation of insulinlike growth factor type 1 receptor (IGF-1R). Radionuclide imaging of IGF-1R in tumors might be used for selection of patients who would most likely benefit from IGF-1R-targeted therapy. The goal of this study was to evaluate the feasibility of in vivo radionuclide imaging of IGF-1R expression in prostate cancer xenografts using a small nonimmunoglobulin-derived binding protein called an Affibody molecule. METHODS: The IGF-1R-binding Z(IGF1R:4551) Affibody molecule was site-specifically conjugated with a maleimido derivative of DOTA and labeled with (111)In. The binding of radiolabeled Z(IGF1R:4551) to IGF-1R-expressing cells was evaluated in vitro and in vivo. RESULTS: DOTA-Z(IGF1R:4551) can be stably labeled with (111)In with preserved specific binding to IGF-1R-expressing cells in vitro. In mice, (111)In-DOTA-Z(IGF1R:4551) accumulated in IGF-1R-expressing organs (pancreas, stomach, lung, and salivary gland). Receptor saturation experiments demonstrated that targeting of DU-145 prostate cancer xenografts in NMRI nu/nu mice was IGF-1R-specific. The tumor uptake was 1.1 ± 0.3 percentage injected dose per gram, and the tumor-to-blood ratio was 3.2 ± 0.2 at 8 h after injection. CONCLUSION: This study demonstrates the feasibility of in vivo targeting of IGF-1R-expressing prostate cancer xenografts using an Affibody molecule. Further development of radiolabeled Affibody molecules might provide a useful clinical tool for stratification of patients with prostate cancer for IGF-1R-targeting therapy.
UNLABELLED: One of the pathways leading to androgen independence in prostate cancer involves upregulation of insulinlike growth factor type 1 receptor (IGF-1R). Radionuclide imaging of IGF-1R in tumors might be used for selection of patients who would most likely benefit from IGF-1R-targeted therapy. The goal of this study was to evaluate the feasibility of in vivo radionuclide imaging of IGF-1R expression in prostate cancer xenografts using a small nonimmunoglobulin-derived binding protein called an Affibody molecule. METHODS: The IGF-1R-binding Z(IGF1R:4551) Affibody molecule was site-specifically conjugated with a maleimido derivative of DOTA and labeled with (111)In. The binding of radiolabeled Z(IGF1R:4551) to IGF-1R-expressing cells was evaluated in vitro and in vivo. RESULTS: DOTA-Z(IGF1R:4551) can be stably labeled with (111)In with preserved specific binding to IGF-1R-expressing cells in vitro. In mice, (111)In-DOTA-Z(IGF1R:4551) accumulated in IGF-1R-expressing organs (pancreas, stomach, lung, and salivary gland). Receptor saturation experiments demonstrated that targeting of DU-145 prostate cancer xenografts in NMRI nu/nu mice was IGF-1R-specific. The tumor uptake was 1.1 ± 0.3 percentage injected dose per gram, and the tumor-to-blood ratio was 3.2 ± 0.2 at 8 h after injection. CONCLUSION: This study demonstrates the feasibility of in vivo targeting of IGF-1R-expressing prostate cancer xenografts using an Affibody molecule. Further development of radiolabeled Affibody molecules might provide a useful clinical tool for stratification of patients with prostate cancer for IGF-1R-targeting therapy.
Authors: Jaya Prabhakaran; Stephen L Dewey; Richard McClure; Norman R Simpson; Mohammed N Tantawy; J John Mann; Wellington Pham; J S Dileep Kumar Journal: Bioorg Med Chem Lett Date: 2017-01-07 Impact factor: 2.823
Authors: Vattoly J Majo; Victoria Arango; Norman R Simpson; Jaya Prabhakaran; Suham A Kassir; Mark D Underwood; Mihran Bakalian; Peter Canoll; J John Mann; J S Dileep Kumar Journal: Bioorg Med Chem Lett Date: 2013-05-16 Impact factor: 2.823
Authors: Sandra Heskamp; Otto C Boerman; Janneke D M Molkenboer-Kuenen; Rutger H T Koornstra; Sabine C Linn; Wim J G Oyen; Winette T A van der Graaf; Hanneke W M van Laarhoven Journal: Mol Imaging Biol Date: 2014-08 Impact factor: 3.488
Authors: Hao Hong; Tapas R Nayak; Sixiang Shi; Stephen A Graves; Brianne C Fliss; Todd E Barnhart; Weibo Cai Journal: Mol Pharm Date: 2014-09-04 Impact factor: 4.939
Authors: Magdalena Malm; Nina Kronqvist; Hanna Lindberg; Lindvi Gudmundsdotter; Tarek Bass; Fredrik Y Frejd; Ingmarie Höidén-Guthenberg; Zohreh Varasteh; Anna Orlova; Vladimir Tolmachev; Stefan Ståhl; John Löfblom Journal: PLoS One Date: 2013-05-10 Impact factor: 3.240